Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Abilify
|
| gptkbp:appointed_by |
oral ingestion
|
| gptkbp:approves |
gptkb:2017
gptkb:FDA |
| gptkbp:contains |
gptkb:aripiprazole
|
| https://www.w3.org/2000/01/rdf-schema#label |
Abilify My Cite
|
| gptkbp:is_associated_with |
reduced hospitalizations
increased treatment adherence |
| gptkbp:is_available_in |
oral solution
tablet form |
| gptkbp:is_compatible_with |
gptkb:mobile_application
|
| gptkbp:is_considered |
a breakthrough in medication adherence
a novel approach to medication management a significant advancement in psychiatry. |
| gptkbp:is_designed_to |
track medication adherence
|
| gptkbp:is_evaluated_by |
cost-effectiveness
patient satisfaction effectiveness in treatment safety in use |
| gptkbp:is_linked_to |
improved patient outcomes
|
| gptkbp:is_part_of |
digital health solutions
personalized medicine approach mental health management Abilify family of medications Otsuka's digital health strategy Otsuka's product portfolio |
| gptkbp:is_promoted_by |
gptkb:hospital
patient education programs |
| gptkbp:is_subject_to |
clinical trials
|
| gptkbp:is_supported_by |
gptkb:municipality
research studies |
| gptkbp:is_used_by |
patients with chronic mental health conditions
|
| gptkbp:is_used_for |
treatment of schizophrenia
treatment of bipolar disorder treatment of major depressive disorder |
| gptkbp:is_used_in |
mental health treatment
psychiatric care |
| gptkbp:manufacturer |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:marketed_as |
first digital pill
|
| gptkbp:provides_information_on |
healthcare providers
|
| gptkbp:requires |
gptkb:theorem
|
| gptkbp:side_effect |
anxiety
dizziness nausea vomiting insomnia |
| gptkbp:suitable_for |
patients with certain medical conditions
children under 18 years old patients with hypersensitivity to aripiprazole |
| gptkbp:technology |
ingestible sensor
|